The University of Chicago Header Logo

Connection

J. Thistlethwaite to Graft Rejection

Back to Details
This is a "connection" page, showing publications J. Thistlethwaite has written about Graft Rejection.
J. Thistlethwaite
Connection Strength
2.989
Graft Rejection
  1. Kidney transplantation: graft monitoring and immunosuppression. World J Surg. 2002 Feb; 26(2):185-93.
    View in: PubMed
    Score: 0.135
  2. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999 Sep 15; 68(5):608-16.
    View in: PubMed
    Score: 0.116
  3. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc. 1998 Jun; 30(4):1369-70.
    View in: PubMed
    Score: 0.106
  4. Successful use of tacrolimus for initial rejection episodes after liver transplantation. Transplant Proc. 1998 Jun; 30(4):1407-8.
    View in: PubMed
    Score: 0.106
  5. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Mar; 30(2):507-8.
    View in: PubMed
    Score: 0.104
  6. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. Transplantation. 1997 Oct 15; 64(7):959-65.
    View in: PubMed
    Score: 0.101
  7. Reversal of accelerated renal allograft rejection with FK 506. Clin Transplant. 1997 Aug; 11(4):251-4.
    View in: PubMed
    Score: 0.100
  8. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. Transplant Proc. 1997 Feb-Mar; 29(1-2):1549.
    View in: PubMed
    Score: 0.096
  9. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation. 1996 Oct 15; 62(7):906-10.
    View in: PubMed
    Score: 0.094
  10. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Transplant Proc. 1996 Aug; 28(4):2136-7.
    View in: PubMed
    Score: 0.093
  11. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. Clin Transplant. 1996 Aug; 10(4):323-32.
    View in: PubMed
    Score: 0.093
  12. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Clin Transplant. 1996 Aug; 10(4):389-95.
    View in: PubMed
    Score: 0.093
  13. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplant Proc. 1996 Apr; 28(2):1014.
    View in: PubMed
    Score: 0.091
  14. Changes in urinary cytokine mRNA profile after successful therapy for acute cellular renal allograft rejection. Transplant Proc. 1995 Feb; 27(1):887-9.
    View in: PubMed
    Score: 0.084
  15. Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts. J Immunol. 1994 Sep 15; 153(6):2738-49.
    View in: PubMed
    Score: 0.082
  16. The use of the T-cell flow cytometry crossmatch to evaluate the significance of positive B-cell serologic crossmatches in cadaveric donor renal transplantation. Transplant Proc. 1990 Aug; 22(4):1897-8.
    View in: PubMed
    Score: 0.061
  17. Aggressive needle biopsy protocol prevents loss of renal allografts to undetected rejection during early posttransplant dysfunction. Transplant Proc. 1989 Feb; 21(1 Pt 2):1890-2.
    View in: PubMed
    Score: 0.055
  18. Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection. Am J Kidney Dis. 1988 Feb; 11(2):94-8.
    View in: PubMed
    Score: 0.052
  19. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine. Transplant Proc. 1987 Feb; 19(1 Pt 3):1901-4.
    View in: PubMed
    Score: 0.048
  20. OKT3 treatment of steroid-resistant renal allograft rejection. Transplantation. 1987 Feb; 43(2):176-84.
    View in: PubMed
    Score: 0.048
  21. Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation. 2005 Jan 27; 79(2):228-35.
    View in: PubMed
    Score: 0.042
  22. Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol. 2003 Jun; 34(6):533-40.
    View in: PubMed
    Score: 0.037
  23. Cutting edge: membrane lymphotoxin regulates CD8(+) T cell-mediated intestinal allograft rejection. J Immunol. 2001 Nov 01; 167(9):4796-800.
    View in: PubMed
    Score: 0.033
  24. Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice. Am J Transplant. 2001 May; 1(1):38-46.
    View in: PubMed
    Score: 0.032
  25. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Hum Pathol. 2001 Feb; 32(2):205-15.
    View in: PubMed
    Score: 0.032
  26. Role of STAT6 signaling in the induction and long-term maintenance of tolerance mediated by CTLA4-Ig. Transplant Proc. 2001 Feb-Mar; 33(1-2):214-6.
    View in: PubMed
    Score: 0.032
  27. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol. 2000 Nov 15; 165(10):5580-7.
    View in: PubMed
    Score: 0.031
  28. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. Transplantation. 2000 Sep 15; 70(5):784-90.
    View in: PubMed
    Score: 0.031
  29. Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival. Transplantation. 2000 Mar 15; 69(5):904-9.
    View in: PubMed
    Score: 0.030
  30. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol. 1999 Sep 01; 163(5):2358-62.
    View in: PubMed
    Score: 0.029
  31. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Am J Kidney Dis. 1999 Jul; 34(1):69-84.
    View in: PubMed
    Score: 0.028
  32. Differential effect of an anti-CD8 monoclonal antibody on rejection of murine intestine and cardiac allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):1239-41.
    View in: PubMed
    Score: 0.028
  33. The role of CD8 and CD4 T cells in intestinal allograft rejection: a comparison of monoclonal antibody-treated and knockout mice. Transplantation. 1999 Jan 15; 67(1):131-7.
    View in: PubMed
    Score: 0.028
  34. Liver transplantation in the first three months of life. Transplantation. 1998 Sep 15; 66(5):606-9.
    View in: PubMed
    Score: 0.027
  35. Role of CD8+ and CD4+ T cells in the rejection of murine intestinal allografts. Transplant Proc. 1998 Sep; 30(6):2592-3.
    View in: PubMed
    Score: 0.027
  36. Inhibition of intestinal allograft rejection by an anti-CD8 monoclonal antibody is not mediated by depletion alone. Transplant Proc. 1998 Jun; 30(4):1069-70.
    View in: PubMed
    Score: 0.026
  37. Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
    View in: PubMed
    Score: 0.026
  38. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients. Transplant Proc. 1998 Jun; 30(4):1435-6.
    View in: PubMed
    Score: 0.026
  39. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Jun; 30(4):1538-40.
    View in: PubMed
    Score: 0.026
  40. An analysis of hepatic retransplantation in children. Transplantation. 1998 May 15; 65(9):1172-8.
    View in: PubMed
    Score: 0.026
  41. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr. 1997 Jul; 131(1 Pt 1):98-104.
    View in: PubMed
    Score: 0.025
  42. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Transplant Proc. 1997 Feb-Mar; 29(1-2):307.
    View in: PubMed
    Score: 0.024
  43. Retransplantation for failed hepatic allografts in children. Transplant Proc. 1997 Feb-Mar; 29(1-2):442-3.
    View in: PubMed
    Score: 0.024
  44. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. Transplant Proc. 1996 Dec; 28(6):3163-4.
    View in: PubMed
    Score: 0.024
  45. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation. 1996 Sep 15; 62(5):594-9.
    View in: PubMed
    Score: 0.023
  46. Long-term outcome of kidney-pancreas transplant recipients with good graft function at one year. Transplantation. 1996 Aug 27; 62(4):451-6.
    View in: PubMed
    Score: 0.023
  47. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996 May 15; 61(9):1365-9.
    View in: PubMed
    Score: 0.023
  48. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplant Proc. 1996 Apr; 28(2):998-9.
    View in: PubMed
    Score: 0.023
  49. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int. 1996 Mar; 49(3):768-72.
    View in: PubMed
    Score: 0.023
  50. Allograft rejection in pediatric recipients of living related liver transplants. Hepatology. 1996 Jan; 23(1):40-3.
    View in: PubMed
    Score: 0.022
  51. Late complications in kidney-pancreas transplant recipients. Transplant Proc. 1995 Dec; 27(6):3118.
    View in: PubMed
    Score: 0.022
  52. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation. 1995 Nov 27; 60(10):1171-8.
    View in: PubMed
    Score: 0.022
  53. OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplant Proc. 1995 Feb; 27(1):852-3.
    View in: PubMed
    Score: 0.021
  54. Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies. Transplantation. 1994 Sep 27; 58(6):681-9.
    View in: PubMed
    Score: 0.020
  55. Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. Lancet. 1993 Sep 25; 342(8874):779-80.
    View in: PubMed
    Score: 0.019
  56. OKT3 induction in pediatric renal transplantation. Pediatr Nephrol. 1993 Feb; 7(1):45-9.
    View in: PubMed
    Score: 0.018
  57. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation. 1993 Jan; 55(1):44-50.
    View in: PubMed
    Score: 0.018
  58. Rat to mouse pancreas xenografts: comparison to islet xenografts. Transplant Proc. 1992 Apr; 24(2):653-4.
    View in: PubMed
    Score: 0.017
  59. Pediatric liver transplantation at the University of Chicago Hospitals. Clin Transpl. 1992; 179-89.
    View in: PubMed
    Score: 0.017
  60. OKT3 therapy for hepatic allograft rejection. Differential response in adults and children. Transplantation. 1991 Jun; 51(6):1207-12.
    View in: PubMed
    Score: 0.016
  61. T lymphocyte activation following OKT3 treatment. Curr Surg. 1990 Nov-Dec; 47(6):458-9.
    View in: PubMed
    Score: 0.016
  62. OKT3 therapy for hepatic allograft rejection: comparison of results in adults and children. Transplant Proc. 1990 Aug; 22(4):1765-6.
    View in: PubMed
    Score: 0.015
  63. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients. Am J Kidney Dis. 1989 Nov; 14(5 Suppl 2):28-34.
    View in: PubMed
    Score: 0.015
  64. Effect of discontinuing or restricting cyclosporine on late renal allograft rejection and function. Transplant Proc. 1989 Feb; 21(1 Pt 2):1641-2.
    View in: PubMed
    Score: 0.014
  65. Effect of massive transfusion during liver transplantation on rejection and infection. Transplant Proc. 1988 Dec; 20(6):1135-7.
    View in: PubMed
    Score: 0.014
  66. Complications and monitoring of OKT3 therapy. Am J Kidney Dis. 1988 Feb; 11(2):112-9.
    View in: PubMed
    Score: 0.013
  67. Potent immunosuppression overcomes immunologic high-risk factors in recipients of cadaveric renal allografts. Am Surg. 1987 Jul; 53(7):407-9.
    View in: PubMed
    Score: 0.012
  68. T cell immunofluorescence flow cytometry cross-match results in cadaver donor renal transplantation. Transplant Proc. 1987 Feb; 19(1 Pt 1):722-4.
    View in: PubMed
    Score: 0.012
  69. Elective conversion from cyclosporine to azathioprine in recipients with stable renal function 6 months after kidney transplantation. Hum Immunol. 1985 Nov; 14(3):314-23.
    View in: PubMed
    Score: 0.011
  70. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation. 1984 Dec; 38(6):695-701.
    View in: PubMed
    Score: 0.010
  71. Transplantation in miniature swine. X. Evidence for non-SLA-linked immune response gene(s) controlling rejection of SLA-matched kidney allografts. Transplantation. 1981 Oct; 32(4):315-20.
    View in: PubMed
    Score: 0.008
  72. CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimulatory pathway. Transplantation. 2001 May 15; 71(9):1351-4.
    View in: PubMed
    Score: 0.008
  73. Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11.
    View in: PubMed
    Score: 0.008
  74. Combined liver and kidney transplantation in children. Transplantation. 2000 Jul 15; 70(1):100-5.
    View in: PubMed
    Score: 0.008
  75. Evaluation of pre- and posttransplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Cooperative Clinical Trials in Transplantation Research Group. Transplantation. 1999 Oct 27; 68(8):1117-24.
    View in: PubMed
    Score: 0.007
  76. Drug-induced acute interstitial nephritis in renal allografts: histopathologic features and clinical course in six patients. Am J Kidney Dis. 1999 Sep; 34(3):540-8.
    View in: PubMed
    Score: 0.007
  77. Modified surgical model of paratopic small bowel transplantation in mice. J Surg Res. 1998 Dec; 80(2):188-93.
    View in: PubMed
    Score: 0.007
  78. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. Transplantation. 1997 Jul 27; 64(2):258-63.
    View in: PubMed
    Score: 0.006
  79. Transplantation of two patients with one liver. Analysis of a preliminary experience with 'split-liver' grafting. Ann Surg. 1990 Jul; 212(1):14-22.
    View in: PubMed
    Score: 0.004
  80. Reexposure to OKT3 in renal allograft recipients. Transplantation. 1988 Feb; 45(2):349-53.
    View in: PubMed
    Score: 0.003
  81. An immunosuppressive protocol compatible with the United States kidney transplant diagnosis related grouping. Transplant Proc. 1987 Feb; 19(1 Pt 3):1959-60.
    View in: PubMed
    Score: 0.003
  82. Effect of class II antigen matching on renal allograft survival in miniature swine. J Exp Med. 1984 Nov 01; 160(5):1495-508.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.